The entire structure of healthcare delivery for effective antibiotics – from research and development, to distribution and rational use – needs to be re-engineered to address the looming global threat of antibiotic resistance, say the authors of a new report, published in The Lancet Infectious Diseases, ahead of European Antibiotic Awareness Day.
The report, which was compiled by an international group of 26 leading experts in the field, presents a comprehensive global overview of the growing problem of antibiotic resistance, its major causes and consequences, and identifies key areas in which action is urgently needed.
Antibiotic resistance arises when bacteria evolve mechanisms to withstand the drugs which are used to fight infection. Recent decades have seen vast increases in the use of antibiotics across medicine and agriculture, and in the absence of adequate regulatory controls, treatment guidelines, and patient awareness, this has led to a huge global surge in antibiotic resistance. The problem is compounded by a desperate shortage of new drugs to treat multi-drug resistant bacterial infections.
According to lead author Professor Otto Cars of Uppsala University in Sweden and ReAct Action on Antibiotic Resistance, “The causes of antibiotic resistance are complex and include human behaviour at many levels of society; the consequences affect everybody in the world. Within just a few years, we might be faced with unimaginable setbacks, medically, socially, and economically, unless real and unprecedented global coordinated actions to improve surveillance and transform the way antibiotics are regulated and developed are taken immediately.”
Addressing these problems will require nothing less than a fundamental shift in how antibiotics are developed, financed, and prescribed.
According to the authors, the paucity of new antibiotic drugs in recent decades has arisen from a combination of significant scientific challenges, low financial returns compared to many other medicines such as those for chronic diseases and the regulatory environment.
Rebuilding the infrastructure of academia and industry to face the threat of antibiotic resistance will not only require national and international political commitment and investment, but also new ways of financing drug development.
Investment in new drugs is based on expectations of large volume sales. In the case of antibiotics, this can lead to aggressive marketing and sales activity, which in turn results in over-prescription, especially when in many countries, financial incentives for doctors and health care systems mean that over-prescription of antibiotics makes sound financial sense.
The authors suggest that academic research institutes and small and medium enterprises across the world need to play a greater role in antibiotic discovery to address the inadequate infrastructure and innovative capacity.